Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237426 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
A Phase 2 study, sponsored by Transcend Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT06237426: Completed Phase 2 study, sponsored by Transcend Therapeutics.
NCT06237426 is a Phase 2 study that has completed, run by Transcend Therapeutics. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06237426, a Phase 2 study, has completed, sponsored by Transcend Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD symptoms will be assessed at each observational visit and if criteria for Relapse has been met, participants may be eligible to receive a course of TSND-201 treatment.
Primary Outcome
The CAPS-5 is a structured interview designed to assess PTSD symptom severity. The total severity score ranges from 0 to 80, with a higher score indicating more severe symptoms.
Interventions
- DRUG Methylone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2025-10-06 |
| Phase | Phase 2 |
What the finished NCT06237426 record still lists
NCT06237426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Methylone is the first listed.
NCT06237426 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06237426 about?
NCT06237426 is a clinical study titled "An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD". This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD s...
What is the current status of trial NCT06237426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2024-03-06. Estimated completion is 2025-10-06.
What interventions are being tested in trial NCT06237426?
The interventions under investigation include: Methylone (DRUG).
Who is sponsoring clinical trial NCT06237426?
This trial is sponsored by Transcend Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06237426's enrollment target sits among peer trials
44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI